Results 141 to 150 of about 1,749 (172)

Prasterone for vulvar and vaginal atrophy in postmenopausal women. [PDF]

Aust Prescr
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Sequential treatment in vulvovaginal atrophy

Climacteric, 2023
Vulvovaginal atrophy (VVA) is a chronic and progressive disease that affects sexuality and quality of life. VVA is preventable and treatable, but requires long-term and often sequential treatment. Sequential treatment consists of designing a strategy that uses one or more medications for a long enough time to achieve the desired benefits with minimal ...
openaire   +2 more sources

Vulvovaginal atrophy – a tale of neglect

Climacteric, 2014
The impact of vulvovaginal atrophy (VVA) on quality of life continues to be underestimated according to an expert review published in this issue of Climacteric1.
Anna Fenton, Nick Panay
openaire   +3 more sources

Ospemifene in the Treatment of Vulvovaginal Atrophy

Annals of Pharmacotherapy, 2014
Objective: To review the pharmacology, efficacy, and safety of ospemifene in the management of dyspareunia. Data Sources: Literature was sought using PubMed (1966-January 2014) and EMBASE (1973-January 2014). Search terms included ospemifene, FC-1271a, dyspareunia, vulvovaginal atrophy, and vaginal atrophy.
Erica F. Pearce, Alicia B. Forinash, Abigail M. Yancey, Kylie N. Barnes   +3 more
openaire   +3 more sources

Injection Treatments for Vulvovaginal Atrophy of Menopause: A Systematic Review

Aesthetic Plastic Surgery, 2023
Injection treatments have been proposed as novel treatment options for Vulvovaginal Atrophy of Menopause (VVA) also known as Genitourinary Syndrome of Menopause (GSM). However, to date data about these treatments are poor.To assess all available injection treatments for VVA.A systematic review was performed by searching five electronic databases for ...
Moccia, Felice, Pentangelo, Paola, Ceccaroni, Alessandra, Raffone, Antonio, Losco, Luigi, Alfano, Carmine   +5 more
openaire   +4 more sources

Treatment of Dyspareunia Secondary to Vulvovaginal Atrophy [PDF]

Nursing for Women's Health, 2014
Declining estrogen levels associated with menopause can result in vulvovaginal atrophy and some degree of dyspareunia for more than half of all women in menopause. In 2013, the U.S. Food and Drug Administration approved ospemifene, a nonhormonal oral medication for the treatment of dyspareunia in menopause.
openaire   +2 more sources

New developments in the management of vulvovaginal atrophy: a comprehensive overview

Expert Opinion on Pharmacotherapy, 2023
Proper recognition and individualized therapy of vulvovaginal atrophy (VVA) is paramount.Assessment of VVA should be performed using several questionnaires in combination with wet mount microscopy to determine Vaginal Cell Maturation Index (VCMI) and infections.
Donders, Gilbert, Donders, Francesca H.W.V.   +1 more
openaire   +3 more sources

Vulvovaginal atrophy in women after cancer

Climacteric, 2019
The number of women surviving longer after a cancer diagnosis is increasing. This means that more awareness regarding their health is required. This review will focus on vulvovaginal atrophy (VVA)/genitourinary syndrome of menopause, one of the most distressing adverse iatrogenic effects of the menopause, secondary to cancer therapies.
P Cox, Nicholas Panay
openaire   +3 more sources